Immix Biopharma (IMMX) Interest & Investment Income (2023 - 2026)
Immix Biopharma (IMMX) reported Interest & Investment Income of $717168.0 for Q1 2026, up 377.41% on a YoY basis from $150219.0 in Q1 2025, and up 230.93% sequentially from $216712.0 in Q4 2025.
Immix Biopharma (IMMX) Interest & Investment Income (2023 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 4 years of Interest & Investment Income data on file, last reported at $717168.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 377.41% year-over-year to $717168.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 24.77% YoY), and the FY2025 full-year result was $555526.0, down 45.4% from the prior year.
- Interest & Investment Income rose to $717168.0 in Q1 2026, from $216712.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $717168.0 in Q1 2026 to a low of $27892.0 in Q1 2023.
- A 4-year average of $220158.0 and a median of $186691.0 in 2023 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income soared 860.52% in 2024 and tumbled 67.06% in 2025, its largest moves.
- Tracing IMMX's Interest & Investment Income over 4 years: stood at $228575.0 in 2023, then declined by 18.69% to $185851.0 in 2024, then grew by 16.61% to $216712.0 in 2025, then jumped by 230.93% to $717168.0 in 2026.
- Business Quant data shows IMMX's Interest & Investment Income at $717168.0 in Q1 2026, $216712.0 in Q4 2025, and $84539.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | 717,168.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 717,168.00 |
| Dec 31, 2025 | 216,712.00 |
| Sep 30, 2025 | 84,539.00 |
| Jun 30, 2025 | 104,056.00 |
| Mar 31, 2025 | 150,219.00 |
| Dec 31, 2024 | 185,851.00 |
| Sep 30, 2024 | 256,680.00 |
| Jun 30, 2024 | 306,915.00 |
| Mar 31, 2024 | 267,908.00 |
| Dec 31, 2023 | 228,575.00 |
| Sep 30, 2023 | 186,691.00 |
| Jun 30, 2023 | 128,848.00 |
| Mar 31, 2023 | 27,892.00 |